questionText: To ask the Secretary of State for Health and Social Care, whether NHS England has approved any drugs with a higher incremental cost-effectiveness ratio than abiraterone for high-risk, non-metastatic prostate cancer in the last five years.
answerText: NHS England has not calculated the incremental cost-effectiveness ratio for any policy proposition because NHS England uses a relative prioritisation process for policy propositions that require funding in line with the published NHS England Specialised C...
heading: Abiraterone